z-logo
Premium
Isoniazid–phytochemical conjugation: A new approach for potent and less toxic anti‐TB drug development
Author(s) -
Swain Shasank S.,
Paidesetty Sudhir K.,
Padhy Rabindra N.,
Hussain Tahziba
Publication year - 2020
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.13685
Subject(s) - isoniazid , mycobacterium tuberculosis , drug , tuberculosis , phytochemical , rifampicin , medicine , drug development , pharmacology , first line , human immunodeficiency virus (hiv) , virology , traditional medicine , pathology
Mycobacterium tuberculosis (Mtb) causes one of the most grievous pandemic infectious diseases, tuberculosis (TB), with long‐term morbidity and high mortality. The emergence of drug‐resistant Mtb strains, and the co‐infection with human immunodeficiency virus, challenges the current WHO‐TB stewardship programs. The first‐line anti‐TB drugs, isoniazid (INH) and rifampicin (RIF), have become extensively obsolete in TB control from chromosomal mutations during the last decades. However, based on clinical trial statistics, the production of well‐tolerated anti‐TB drug(s) is miserably low. Alternately, semi‐synthesis or structural modifications of first‐line obsolete antitubercular drugs remain as the versatile approach for getting some potential medicines. The use of any suitable phytochemicals with INH in a hybrid formulation could be an ideal approach for the development of potent anti‐TB drug(s). The primary objective of this review was to highlight and analyze available INH–phytochemical hybrid research works. The utilization of phytochemicals through chemical conjugation is a new trend toward the development of safer/non‐toxic anti‐TB drugs.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here